

APPLICATION UNDER UNITED STATES PATENT LAWS

Atty. Dkt. No. PW 279455/Z70429/UST
(M#)

JC08 Rec'd PCT/PTO 08 MAY 2001

Invention: METHOD FOR IDENTIFYING INHIBITORS OF IPC SYNTHASE

Inventor (s): SCHNELL, Norbert Friedemann
CHAVDA, Jini Suberna

Pillsbury Winthrop LLP
Intellectual Property Group
1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Attorneys
Telephone: (202) 861-3000

This is a:

- ☐ Provisional Application
- ☐ Regular Utility Application
- ☐ Continuing Application
 - ☒ The contents of the parent are incorporated by reference
- ☒ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application
- ☐ Substitute Specification
 - Sub. Spec Filed _____
 - in App. No. _____ / _____
- ☐ Marked up Specification re
Sub. Spec. filed _____
In App. No. _____ / _____

SPECIFICATION

-1-

METHOD FOR IDENTIFYING INHIBITORS OF IPC SYNTHASEINS
AI

The present invention relates to a cell-based screen for inhibitors of fungal inositolphosphoryl-ceramide (IPC) synthase, an important antifungal target.

5 Inhibitors of fungal IPC synthase are potent and selective antifungal agents for example Aureobasidin, Khafrefungin and Rustmicin) as identified by several research groups and pharmaceutical companies.

However, all such compounds are natural products that are difficult to produce, handle and administer to a patient (for example, they may have unsuitable pharmacokinetics).

10 Therefore it is highly desirable to obtain other novel chemical compounds selectively inhibiting the same target (a fungal IPC synthase) but without the intrinsic disadvantages displayed by the currently known inhibitors. Screening for such novel chemicals as well as optimisation of already available "leads" (ie. optimisation of a known inhibitor in a structure-based design or lead optimisation) will require an assay for IPC synthase activity that can be
15 performed at a sufficiently high throughput.

All currently available biochemical assays for IPC synthase are involved and very labour-intensive.

Nagiec et al (Journal of Biological Chemistry, Vol 272 No 15, pp 9809-9817 (1997))) describe the complementation of an IPC synthase gene defect in a mutant strain of *S.*

20 *Cerevisiae* by the *AUR1* gene. The mutant strain has a deletion of the *LCB1* gene and a point mutation that creates the suppressor gene *SLC1-1*. The *lcb1* mutation prevents sphingolipid synthesis and the *SLC1-1* gene enables the cells to make phospholipids and remain viable. (Use of capital letters implies a functional gene or a gain of function mutation such as *SLC1-1* whereas small letters indicate a non functional allele such as *lcb1*). Using this the authors
25 were able to isolate a mutant strain defective in IPC synthase and to isolate a gene *AUR1* which complemented the IPC synthase defect and restored IPC synthase activity. The authors conclude that IPC synthase is the target for antifungal agents such as aureobasidin. They postulate that it should be possible to develop high throughput screens to identify new inhibitors of IPC synthase to combat fungal diseases.

30 However we have found that whilst a similar strain of *S. cerevisiae* (*lcb1* / *SLC1-1*) is viable, the strain grows very poorly and is extremely sensitive to any environmental

09831290 050801

-2-

influences such as for example freezing. This strain is simply not robust enough for screening purposes.

We now provide a robust cell-based assay for identifying selective IPC synthase inhibitors. This assay is based on our development of an *S. cerevisiae* strain wherein the production of compensatory phospholipids is enhanced.

Therefore in a first aspect of the present invention we provide a screening assay for identifying a selective IPC synthase inhibitor which assay comprises contacting a test compound with engineered cells whose capability to synthesize sphingolipids depends on the addition of exogenous phytosphingosine and which are capable of sustained growth via compensatory phospholipids, adding phytosphingosine, and determining IPC synthase inhibition by the test compound by reference to any cell growth inhibition.

Any convenient host cell strain may be used provided that it can function as a host for a fungal IPC synthase gene. Convenient hosts include fungi that are manipulatable genetically such as *S. cerevisiae* but also others such as *Candida albicans*, *Candida glabrata*, *Aspergillus* sp. or *Schizosaccharomyces pombe*. Convenient sources for the AUR1 gene are pathogenic (also phytopathogenic) fungi as outlined above and others such as *Ashbya* sp., *Fusarium* sp., *Trichoderma* sp., *Cryptococci*, *Blastomyces*, and *Histoplasma*.

Whilst we do not wish to be bound by theoretical considerations the compensatory phospholipids are believed to be novel glycerophospholipids that may compensate for one or more functions of sphingolipids essential for vegetative growth (Lester et al, J.Biol.Chem., 1993, 268, 845-856).

In a further aspect of the invention we provide engineered cells whose capability to synthesize sphingolipids depends on the addition of exogenous phytosphingosine and which are capable of sustained growth via compensatory phospholipids

By "sustained growth" we mean no significant decrease of viable cell counts during a growth period (ie. cell-death is negligible compared to cell growth). The strain also has to be capable of one or more of the following: being stored for prolonged periods, for example up to three or six months or longer; storage in liquid medium; or capable of being frozen and revived. The engineered cells of the invention are capable and robust enough for routine use in high throughput assay procedures. In general they will have generation times compatible with growth assays (ie. not more than 4 hours per doubling) and final optical densities reached

-3-

of more than 4 OD (at 600 nm and 1 cm path length). These parameters allow complete assessment of a host strain's growth within less than 30 hours.

A convenient host strain for use in the assay methods of the invention is an *lcb1* / SLC1-1 strain. More conveniently it will include a selection marker, for example the *lcb1* gene may be directly replaced by an amino acid biosynthetic gene (such as LEU2, TRP1 or HIS3) or antibiotic resistance such as Geneticin (G418).

Adapting host cells for sustained growth is for example achieved by enhancing expression of the compensatory mutant SLC1-1 allele. We have surprisingly found that can be achieved by cloning the SLC1-1 gene onto a multi-copy plasmid (pYES2-LEU2d- GPD3- SLC1-1 = pNS149) under control of the glyceraldehyde 3-phosphate dehydrogenase promoter. Use of a multi-copy pGPD-SLC1-1 promoter/gene construct yielded a strain with much improved growth characteristics, improved growth rate, final optical density and resistance to freezing. In summary it provided for the first time a host strain which is robust enough for screening purposes.

The GPD3 is an example of a very strong constitutive promoter in *S. cerevisiae*. Other glycolytic enzymes such as Phosphoglycerate Kinase (PGK), Enolase 1 (ENO), Pyruvate Kinase (PYK) and Fructose-Bisphosphate Aldolase II FBA are convenient sources of other such promoters.

Therefore in a further aspect of the invention we provide an engineered host strain *S. cerevisiae* (*lcb1* / pGPD-SLC1-1).

The invention will now be illustrated but not limited by reference to the following Examples and Figures:

Examples

Example 1 Construction of the IPC synthase screening strain (*lcb1::kanMX*, pNS149 (pGPD3-SLC1-1))

(i) Generation of a *LCB1* deletion strain

4

As *LCB1* is an essential gene, only one allele of a diploid cell can be deleted without loss of survival. Added phytosphingosine can, however, substitute for an intact *LCB1* gene. Technically, one *LCB1* allele of a diploid *S. cerevisiae* strain (JK9-3daa - Kunz, J. et al, Cell, 1993, 73, 585-596) was disrupted using the kanamycin resistance cassette as described by Wach et al, Yeast, 1996, 12, 259-265.

PCR primers used to create the *LCB1* deletion (*lcb1::kanMX*)

5' Primer :

GCAATGGCACACATCCCAGAGGTTTTACCCAAATCAATACCGATTCCGGCATTTA
TTGCAGCTGAAGCTTCGTACGCTGCAG

3' Primer:

CTATTTTATTATTAGATTCTTGGAACAGGCAAGGATGGACTGCTTGACCCGCA
TAGGCCACTAGTGGATCTG

Disruption of *LCB1* and its replacement by kanMX was verified by PCR (using primers 5' of the deleted region directed towards the gene and within kanMX facing towards the promoter). Sporulation of the heterozygous diploid (*LCB1/lcb1::KanMX*) and tetrad dissection yields 2 kanamycin-sensitive colonies per tetrad when grown on YPD (Sherman et al, Methods in Yeast Genetics, 1986, Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y. media) without phytosphingosine, however if the ascus is dissected on media containing 10mM phytosphingosine this results in 4 colonies per tetrad, two of which are resistant to kanamycin (and therefore are *lcb1::kanMX*).

(ii) Generation of a SLC1-1 allele cloned into a multi-copy plasmid

The dominant *SLC1-1* allele was generated from the wildtype allele by PCR regenerating the sequence as described by Nagiec *et al.* (*op cit*). The mutant *SLC1-1* allele differs from the wildtype allele by a single nucleotide which changes Glutamine 44 in the wild-type protein to Leucine in the suppressor protein. According to the literature (Nagiec *et al.*, *op cit*) this mutation should rescue the *lcb1::kanMX* strain, allowing growth on media without added phytosphingosine.

-5-

The *SLC1-1* was amplified from genomic DNA by PCR (creating the point mutation via a mismatch in the 5' primer) and cloned into expression plasmids (eg pYES2-Leu2 (Invitrogen), modified by an inserted Leu2 selection marker = pNS144) using BamHI (5') and SphI (3') as insertion sites (to give pNS145). After transformation into *lcb1::kanMX* (3), (selection SGal-leucine, no phyto-sphingosine added) microcolonies were established after 12 days of incubation proving and confirming the suppressing function of *SLC1-1*. However, the viability of these transformants was extremely poor and they were not maintainable in liquid culture. Establishment of frozen stocks from the colonies also failed. A similar phenotype was also observed if the homologous *SLC1* promoter was used instead of *Gall* (pNS148).

Primers to generate *SLC1-1* by PCR. Restriction sites are shown in bold. The point mutation generating Leu 44 is shown underlined in italics

15 *SLC1-1* 5'
CGCGGATCCATGAGTGTGATAGGTAGGTTCTTGTATTACTTGAGGTCCGTGTTGGT
CGTACTGGCGCTTGCAGGCTGTGGCTTTTACGGTGTAATCGCCTCTATCCTGTGCA
CGTTAATCGGTAAGCAACATTTGGCTCTGTGG

20 *SLC1-1* 3'
ACATGCATGCTTAATGCATCTTTTTTACAGATGAACC

(iii) Generation of a GPD3-driven *SLC1-1* allele

25 We postulated that the poor viability of the *lcb1::kanMX* pNS145 strain might be due to insufficient expression of *SLC1-1*, so increased expression was attempted. We placed the *SLC1-1* gene under control of the glyceraldehyde-3-phosphate dehydrogenase GPD3 (=TDH3), promoter (Norbeck et al, Yeast, 1997, 16, 1519-1534).

050301 050301 050301

SUB
B2

